Retroviral propagation crucially depends on reverse transcriptase (RT). We have developed murine models to test the biological effectiveness of the RT inhibitor suramin. The drug was active in our assay system, which includes (i) inhibition of RT activity in the murine T-cell tropic virus SL3-3 and Rauscher murine leukemia virus (MuLV), (ii) inhibition of plaque formation in the XC plaque assay, (iii) inhibition of viral infection of cultured murine T cells, and (iv) inhibition of splenomegaly induced by Rauscher MuLV in BALB/c mice. Suramin decreases viral titers significantly, even if started 36 hr after infection. Viral titers and number of infected cells increased to control levels after removal of the drug. BALB/c mice treated i.v. with 40 mg of suramin per kg twice per week following infection with Rauscher MuLV showed a 35% decrease in splenomegaly. Suramin is an active antiretroviral agent whose effect on retroviral propagation is reversible. We conclude that it acts as a virustatic drug and that long-term administration of suramin will be necessary if it is used for experimental treatment of human retroviral illnesses such as the acquired immune deficiency syndrome.
The importance of retroviruses in inducing neoplasia and immunosuppression in animal species has long been recognized (1) . Their role in human diseases is just beginning to be understood. The human T-cell leukemia virus type I (HTLV-I) has been causally linked to certain human T-cell leukemias and lymphomas (2) . The virus was first isolated from a patient thought to have mycosis fungoides (3) and is endemic in certain areas of the Caribbean islands (4, 5) and Japan (6, 7) . HTLV-I-positive leukemia/lymphoma has a grave prognosis, and conventional chemotherapeutic regimens are ineffective in giving long-term survival (8) . The human Tlymphotropic virus type III (HTLV-III/LAV) (9, 10) is believed to cause the acquired immune deficiency syndrome (AIDS) (11) . Like HTLV-I-positive T-cell malignancies, fully developed AIDS has a grave prognosis, and to date no curative therapy exists (12) . The number of cases has been rising steadily.
HTLV-III can infect the brains of some AIDS patients (13) . In tissue culture, it can grow not only in T-helper cells (9, 10, 14) but also in monocytic, endothelial, and glioblastoma cell lines (unpublished data) . Such cells could represent a natural reservoir in virus-positive individuals.
Clearly, breaking the viral life cycle by therapeutic interventions could be a major step toward stemming retroviral epidemics. Pharmacological agents designed to interfere with retroviral functions such as reverse transcription could be important therapeutic means, possibly together with immunological reagents. Effective drugs need to have a high therapeutic index and little or no depression of bone marrowderived cells, especially granulocytes. Presently, the major causes of death in AIDS patients are severe infections due to the lack of cellular immunity (15, 16) . Most patients, however, do not present with bacterial sepsis like neutropenic cancer patients following cytotoxic chemotherapy.
The antitrypanosomal drug suramin (17) seems to be a candidate antiretroviral drug. De Clercq found that it reversibly inhibits the reverse transcriptase (RT) activity of avian and murine viruses (18) . In a recent report, suramin inhibited the cytopathic effects of HTLV-Ill on T-helper cells cocultivated with a virus-producing cell line (19) . Most importantly, there was little cytotoxicity at suramin levels able to prevent cytopathic effects. Suramin has, however, shown renal toxicity in humans treated for trypanosomiasis (17) . This may prevent it from becoming a drug useful in the treatment of human retroviral diseases. Analogues of suramin with diminished renal toxicity may have to be tested. What is clearly needed is a screening procedure that allows rapid detection of useful antiretroviral agents, first by in vitro analysis. Agents that pass this first round would then be selected for analysis in animals.
We report the systematic evaluation of suramin in murine retroviral systems in vitro and in vivo, using the T-cell tropic virus SL3-3 (20) and the erythrotropic Rauscher murine leukemia virus (MuLV) (21) . This latter agent was chosen for its short latent period for disease induction. Susceptible mice develop palpable splenomegaly within 2 weeks and usually succumb to the leukemia in 30-40 days. The degree of splenomegaly is proportional to the viral titer (22) . The short latent period allows rapid determination of effective dosage. Biological effectiveness against T-cell tropic retroviruses can be studied in mice susceptible to SL3-3-induced leukemia/lymphoma. Onset of disease due to SL3-3 typically occurs between 60 and 90 days following injection of susceptible newborn mice (23, 24) . The SL3-3 virus is of particular interest since chronic viremia precedes development of T-cell lymphoma. Agents capable of significant reduction of viremia and development of lymphoma due to SL3-3 should be active against other retroviruses with T-cell tropism and longer latent periods.
MATERIALS AND METHODS
Cell Lines. SC-1 and XC cells, obtained from M. Cloyd (Duke University), were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum. NIH 3T3 cells were grown in DMEM supplemented with 10% calf serum. Murine L691 cells, obtained from N. Rosenberg (Tufts University), were grown in RPMI 1640 medium supplemented with 10% fetal calf serum.
Abbreviations: RT, reverse transcriptase; HTLV, human T-cell leukemia virus; MuLV, murine leukemia virus; AIDS, acquired immune deficiency syndrome; pfu, plaque-forming units.
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Viruses. SL3-3 virus (20) was prepared by transfecting the cloned provirus (23) Ag/ml, cells infected in the absence of suramin yielded a viral titer of 3.5 x 105 pfu/ml. At 50 ,g/ml, the titer was reduced to 6 x 102 pfu/ml, and no plaques were detected at 100 ,ug of suramin per ml. Fig. 2B ,jg of suramin per ml. Inhibition of plaque formation in the XC plaque assay by suramin (Fig. 2) correlated with the suppression of viral titers when T cells were infected in the presence of suramin (Fig. 3) . The somewhat greater inhibitory effect of suramin on suppressing titers of infected SC-1 cells may be explained by higher intracellular concentration of the drug. Suramin is thought to be taken up by cells in protein-suramin complexes. In animals it becomes concentrated in lysosomes of macrophages (17 immediately thereafter are sufficient to prevent viral infection of T cells. L691 cells were pretreated for 24 hr with 100
Ag of suramin per ml followed by infection with SL3-3 virus in the presence of the same concentration of the drug.
Uninfected L691 cells and L691 cells infected with the virus in the absence of suramin served as controls. When the supernatant of the control cells infected in the absence of suramin 17 days later showed a high level of RT activity, the number of virus-positive cells was assayed in the XC infectious center assay. Suramin-treated cells were washed to remove the drug before they were added to SC-1 cells. The results are shown in Fig. 4A . Sixty percent of the positive control L691 cells were virus positive, whereas infection of L691 cells in the presence of 100 pug of suramin per ml yielded 0.09% virus-positive cells. Suramin was removed from an aliquot of these latter cells, and all cultures were incubated again. Three days after removal of suramin, the supernatant of the L691 cells initially infected in the presence of 100 ,g of suramin per ml showed very high RT activity. XC infectious center assays performed subsequently showed a dramatic increase in the number of virus-positive cells (Fig.  4B) . To confirm these results, L691 cells were pretreated with various concentrations of suramin and infected in the presence of the drug as described above. Three days after viral infection, suramin was washed out. RT activities measured 10 days later were in the same range as those of control samples infected in the absence of suramin. Viral titers of tissue culture supernatants of L691 cells pretreated and infected in the presence of suramin at 100 ,ug/ml for 3 days followed by growth in regular medium for 1 week were virtually identical to those of control cultures infected in the absence of suramin (data not shown). We conclude that only very few cells become infected by high titers of virus in the Tissue culture supernatants were tested for plaque formation in the XC plaque assay (top panels) and for RT activity (bottom panels).
were infected in the presence ofPolybrene for 3 hr with SL3-3 virus. Twelve or 36 hr after the virus had been washed out, various concentrations of suramin were added to the tissue culture medium, and the cells were grown for 10 days in suramin-containing medium. The supernatant was assayed subsequently for infectious virus particles and RT activity (Fig. 5) . Suramin was able to decrease the titer of infectious virus, but the decrease was less pronounced when suramin was begun 36 hr after viral infection. The fact that suramin can still depress viral titers 36 hr after viral infection could be explained by its ability to prevent newly released viral particles from infecting neighboring cells, thereby limiting viral spread.
Effect of Suramin on Granulocyte and Macrophage Precursors. Bone marrow cells were isolated from the femurs and tibias of BALB/c mice and plated in the presence of various concentrations of suramin. Colony formation was not significantly suppressed at suramin concentrations up to 100 ,ug/ml, but at 300 ,ug/ml it was completely inhibited (data not shown).
In Vivo Testing of Suramin in Rauscher MuLV-Infected BALB/c Mice. A total of 79 mice was treated either with virus alone, with suramin only, or with virus and suramin; 10 untreated mice were used as control (Table 1) . A 35% reduction in virus-induced splenomegaly was seen at a dose of 40 mg/kg i.v. given twice weekly (P < 0.0001 by t test), whereas the dose of 10 mg/kg i.v. given by the same schedule failed to decrease the spleen weight. This is not surprising, as shown by the suramin levels that were measured in pooled plasma samples 24 hr after the last dose of suramin. A dose of 40 mg/kg twice weekly yielded suramin levels between 58 and 83 pug/ml, whereas 10 mg/kg only resulted in plasma levels of 12-14 pug/ml. The biological effectiveness of these suramin levels correlates well with the in vitro analysis discussed above. Since we have observed neither drug toxicity nor maximally effective plasma levels, the dose of suramin can be further escalated.
Pretreatment of the mice with suramin at 40 mg/kg 24 hr before administration of the virus, followed by the same dose given twice weekly, yielded a decrease of virally induced splenomegaly by 25% (P = 0.00042). This decrease was less than that observed at the same dose level but without pretreatment. Comparison of the two groups receiving virus and suramin at 40 mg/kg per dose showed that the mean spleen weight without pretreatment was less than that observed with pretreatment (P = 0.044, one-sided test). This statistically significant decrease in effectiveness of suramin, if it is given before viral infection, may be explained by side effects of suramin on the host. At relatively high doses, suramin has been noted to be lympholytic (17) . The much greater antiviral effect of suramin may thus be somewhat diminished by immunosuppression. Also of note is the slight, but dose-dependent, development of splenomegaly in the mice treated with suramin only (P < 0.001, JonckheereTerpstra method).
DISCUSSION
The spreading epidemic of AIDS calls for therapeutic interventions. To date, no specific therapy is available for prevention or treatment of viremia. Development of inhibitors of viral RT should have high priority for the following reasons: (i) RT is a virally encoded enzyme, (ii) normal host cells do not have RT activity, (iii) without functioning RT, viral infection cannot take place, and the viral life cycle is interrupted (31 (19) .
Candidate drugs passing these first series of tests successfully are selected for in vivo testing by using the Rauscher MuLV/BALB/c system for expeditious determination of effective antiretroviral dosages. Because of the rapid onset of Rauscher MuLV-induced erythroleukemia, answers can be obtained within 3 weeks. The ability of the same drug dosage to suppress infection of T cells in vivo can be studied next, by using strains of mice susceptible to SL3-3 virus. The animals can be examined for SL3-3 viral titers as well as for development of thymic lymphoma and leukemia. Drug levels in the mice are determined to facilitate subsequent clinical trials of promising therapeutic agents.
The major advantage of such a system is the rapidity with which answers can be obtained. Unlike HTLV-III, which has an incubation time of2 or even 5 years, SL3-3 induces disease in about 60-90 days. The continuing rapid spread of HTLV-III infection should make the drug screening system we have described highly attractive.
